COMMUNIQUÉS West-GlobeNewswire

Erasca Announces Positive Preliminary Phase 1 Dose Escalation Data for Potentially Best-in-Class Pan-RAS Molecular Glue ERAS-0015 in KRAS-Mutant Solid Tumors
27/04/2026
Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS G12X PDAC: 40% [...]
Intellia Announces Proposed Public Offering of Common Stock
27/04/2026
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core [...]
Australian Patent Granted to NurExone Covering Stem Cell-Derived Exosome Production
27/04/2026
Sheba medical center researcher to present NurExone’s exosome optic nerve regeneration work at ISCEV@Denver TORONTO, Ontario and HAIFA, Israel, April 27, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) ( [...]
Cellectis Presents Epigenetic Editing Platform to Turn Genes Off Without Altering DNA at the ASGCT Annual Meeting
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving [...]
TOMI Environmental Positioned for Accelerated Growth as Robotaxi Market Rapidly Expands
27/04/2026
TOMI Leverages Proprietary SteraMist iHP Technology to Scale Global Fleet Disinfection FREDERICK, Md., April 27, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in [...]
The Joint Corp. Signs Asset Purchase Agreement to Sell 45 Corporate-Owned Clinics in Southern California
27/04/2026
- Effectively Positions The Joint as a Pure-play Franchisor - SCOTTSDALE, Ariz., April 27, 2026 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT) (the “Company”), the nation's largest franchisor of chiropractic care [...]
Protara Therapeutics to Present Updated, Interim 12-Month Data from the Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients at the American Urological Association Annual Meeting
27/04/2026
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage biotechnology company developing transformative therapies for the treatment of cancer and rare diseases, today [...]
Outset Medical to Report First Quarter 2026 Financial Results on Thursday, May 7, 2026
27/04/2026
SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with [...]
Sana Biotechnology Announces Oral Presentation Highlighting Preclinical Data from in vivo CAR T SG293 at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting
27/04/2026
SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that an abstract highlighting [...]
Umoja Biopharma Announces Unveiling of UB-VV500 in Upcoming Poster Presentation at the American Society of Gene & Cell Therapy Annual Meeting
27/04/2026
- Industry’s First Combination BCMA x GPRC5D In Vivo CAR T Cell Therapy for the Treatment of Multiple Myeloma - SEATTLE, April 27, 2026 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), a clinical-stage biotechnology [...]
Addition Therapeutics Announces Multiple Oral and Poster Presentations at the American Society of Gene & Cell Therapy (ASGCT) 29th Annual Meeting
27/04/2026
“Best of both modalities” approach combines the efficacy, safety and scalability of RNA therapeutics with the multi-year durability of gene therapies Portfolio prioritizes rare, severe, lifelong non-genetic and genetic [...]
Oruka Therapeutics Announces Proposed $500 Million Underwritten Public Offering
27/04/2026
MENLO PARK, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. (Nasdaq: ORKA), a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis and [...]
Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
27/04/2026
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, [...]
Beta Bionics to Present at the Bank of America Securities Health Care Conference
27/04/2026
IRVINE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at the [...]
AB Science annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers
27/04/2026
COMMUNIQUE DE PRESSE AB SCIENCE annonce un accord final sur la renégociation des modalités de remboursement de ses emprunts avec l’ensemble de ses créanciers financiers AB Science est parvenue à un accord définitif avec [...]
AB Science announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors
27/04/2026
PRESS RELEASE AB SCIENCE announces a final agreement on the renegotiation of the repayment terms of its loans with all of its financial creditors AB Science has reached a final agreement with its financial creditors [...]
Virbac : Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025
27/04/2026
Communiqué de mise à disposition du Rapport Annuel de Virbac au 31 décembre 2025. Le Groupe annonce avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers son Rapport Annuel au format [...]
Virbac : Public release of Virbac Annual Report at 31 December 2025.
27/04/2026
Public release of Virbac Annual Report at 31 December 2025. The Group released and filed its 2025 Annual Report with the French “Autorité des marchés financiers”, at the ESEF format. Additionally, the report is attached [...]
Virbac : Rapport Annuel Virbac au 31 décembre 2025 (ESEF)
27/04/2026
Veuillez trouver le Rapport Annuel du Groupe au format ESEF au 31 décembre 2025 Pièce jointe Rapport_Annuel_Virbac_2025_XBRL

Pages